The Food and Drug Administration today released a briefing document on Pfizer’s BNT162b2 COVID-19 vaccine candidate that confirms the drug maker’s claims of the vaccine’s efficacy and safety. The document is among a host of materials released in advance of the key Dec. 10 meeting of FDA’s vaccine advisory committee in which Pfizer’s request for an emergency use authorization for BNT162b2 will be considered. FDA mirrored Pfizer’s application in its findings, stating that there are no specific safety concerns across key categories of race, age, ethnicity, medical co-morbidities or prior COVID-19 infection.

However, the agency notes that more data is needed to understand the vaccine’s efficacy against asymptomatic infection, which FDA says is possibly lower than its effectiveness against symptomatic infection. FDA also would like to see additional testing on the vaccine’s effectiveness in preventing the virus’ transmission.

Related News Articles

Headline
The Senate Finance Committee Feb. 4 voted 14-13 to advance Robert F. Kennedy Jr.’s nomination for secretary of the Department of Health and Human Services. A…
Headline
Respiratory illness activity remains high across the country, according to the latest data from the Centers for Disease Control and Prevention. Seasonal flu…
Headline
The Occupational Safety and Health Administration Jan. 13 announced that it terminated efforts to establish a final COVID-19 safety standard to protect workers…
Headline
The Department of Health and Human Services Dec. 10 amended the Public Readiness and Emergency Preparedness Act declaration for COVID-19, extending liability…
Headline
AHA's latest social media toolkit for encouraging vaccination against the flu and COVID-19 provides fall-themed social media posts and graphics. Download the…
Headline
The Centers for Disease Control and Prevention last week endorsed a recommendation for people aged 65 and older and for immunocompromised individuals to…